Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13689289 | 0.98 | HPGD (0.48) | HPGDHSD11B1ALDH1A1ATMNPC1 | |
| SCHEMBL13689285 | 0.86 | CYP1A2 (0.47) | HPGDHSD11B1NPC1RAB9A | |
| SCHEMBL23314187 | 0.84 | KDM5A (0.46) | HPGD | |
| SCHEMBL22526083 | 0.83 | MAPT (0.40) | HPGDHSD11B1ALDH1A1NPC1RAB9A | |
| SCHEMBL25123608 | 0.83 | MAPT (0.37) | HPGDHSD11B1NPC1RAB9AKLK7 | |
| SCHEMBL13479855 | 0.82 | HSD11B1 (0.42) | HPGDHSD11B1ALDH1A1ATMNPC1 | |
| SCHEMBL13282268 | 0.80 | GNAI3 (0.45) | HSD11B1ALDH1A1ATMTP53 | |
| SCHEMBL13254062 | 0.79 | HRH3 (0.40) | HSD11B1ALDH1A1ATM | |
| SCHEMBL23806147 | 0.77 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL18875742 | 0.77 | CCR2 (0.38) | HSD11B1ALDH1A1ATMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2021-01-14 | — | — | US | disclosed |
| US-10544154-B2 | Opioid receptor antagonist prodrugs | NIRSUM LABORATORIES, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20190308988-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20130295261-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | SENOMYX, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-8420145-B2 | Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080051353-A1 | Avermectin And Avermectin Monosaccharide Substituted In The 4\"- And 4\" Position Respectively | SYNGENTA CROP PROTECTION, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| CN-87108356-A | PYRIMIDINE DERIVATIVES | — | 1988-09-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | HPGD 2028/4885HSD11B1 3908/4885ALDH1A1 1991/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HPGD 2426/4885HSD11B1 2329/4885ALDH1A1 2369/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | HPGD 2028/4885HSD11B1 3908/4885ALDH1A1 1991/4885 |
| US-20090042973-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | HPGD 2979/4885HSD11B1 2701/4885ALDH1A1 1604/4885 |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | CRBN, IKZF1, IKZF3 | HPGD 4729/4885HSD11B1 2520/4885ALDH1A1 3827/4885 |
| US-10544154-B2 | Opioid receptor antagonist prodrugs | OPRM1, OPRK1, OPRL1 | HPGD 567/4885HSD11B1 1024/4885ALDH1A1 725/4885 |
| US-20190308988-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRM1, OPRK1, OPRL1 | HPGD 567/4885HSD11B1 1024/4885ALDH1A1 725/4885 |
| US-20080051353-A1 | Avermectin And Avermectin Monosaccharide Substituted In The 4\"- And 4\" Position Respectively | CCR6, CHRM4, CHRM5 | HPGD 4789/4885HSD11B1 1465/4885ALDH1A1 3420/4885 |
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | HPGD 2473/4885HSD11B1 4484/4885ALDH1A1 3141/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HPGD 2426/4885HSD11B1 2329/4885ALDH1A1 2369/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | HPGD 2028/4885HSD11B1 3908/4885ALDH1A1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.